United States Human Biospecimens Market Size, Share, Growth, and Industry Analysis, By Specimen Type (Tissue SpecimensFFPE (Formalin-Fixed Paraffin-Embedded) TissueFresh Frozen TissueTumor BiopsiesNormal Tissue Samples, BiofluidsWhole BloodPlasmaSerumUrineSalivaCSF (Cerebrospinal Fluid)Fastest Growing: Plasma, Cellular MaterialPBMCs (Peripheral Blood Mononuclear Cells)Buccal CellsStem Cells, Nucleic AcidsGenomic DNARNActDNA/cfDNA (circulating tumor/DNA) – Fastest Growing), By Ap (Cancer Research, Drug Discovery and Development, Diagnostics and Biomarker Discovery, Translational and Genomic Research) and Forecast, 2026-2034

United States Human Biospecimens Market Trends

Digital Biobanking, AI Pathology, and Data-Rich Specimens Reshape Procurement

Biobanking is shifting from inventory-centered repositories toward digitally searchable, molecularly characterized sample ecosystems. All of Us made biospecimen information covering more than 370,000 available participant samples accessible through its controlled Researcher Workbench environment in 2026, including blood DNA, saliva DNA, serum, and plasma availability. Meanwhile, commercial repositories operate at multi-million-specimen scale; Precision for Medicine reports biorepositories containing more than 10 million specimens.

Technology adoption increasingly combines digital pathology, AI, multiomics, automated storage, and integrated LIMS workflows. Discovery Life Sciences and PathAI announced an at-scale commercial-biobank deployment of AI pathology technologies in January 2025. Industry supply remains structurally constrained despite enormous inventory: iSpecimen reports that more than 80% of researchers have limited studies because of insufficient biospecimen quantities and more than 80% because of quality problems, despite an estimated 800+ million specimens stored globally and over 3 billion clinical specimens discarded annually.

United States Human Biospecimens Market Drivers

Precision Oncology and Biomarker Programs Accelerate Sample Utilization

Precision oncology, companion diagnostics, genomic profiling, and translational drug development are increasing requirements for clinically annotated tissue, plasma, PBMC, DNA, and RNA cohorts. More than 11,100 researchers use All of Us data, while participant information contributes to over 21,327 health studies and the program has collected more than 612,000 biosamples. Commercial sourcing platforms simultaneously address an environment where over 80% of researchers report specimen-quantity limitations and over 80% report quality-related constraints, strengthening demand for standardized, deeply annotated and research-ready material.

United States Human Biospecimens Market Restraints

Consent, Security, Quality, and Chain-of-Custody Requirements Increase Complexity

Human sample commercialization faces stringent consent, privacy, traceability, quality-control, and cross-border governance requirements. NIH's enhanced security policy became effective October 24, 2025 and applies to relevant NIH-funded collection, storage, use, and distribution of U.S.-person biospecimens. The operational burden extends across tissue, blood, urine, cells and other human-derived material, while the industry simultaneously faces the >80% researcher-reported problems associated with insufficient quantity and quality. These requirements increase validation workload, documentation intensity, storage costs, and procurement lead times.

United States Human Biospecimens Market Opportunities

Prospective Collections and Multiomics-Ready Cohorts Create Higher-Value Supply

Prospective collection enables sponsors to specify disease stage, treatment history, demographics, processing time, sample volume, and molecular characteristics before procurement. Commercial networks increasingly combine banked inventories with customized collections: Precision for Medicine reports more than 10 million repository specimens, while iSpecimen provides access to millions of specimens and patients through its provider network. The opportunity is reinforced by 370,000+ participant samples represented in the 2026 All of Us biospecimen table, creating expanding scope for genotype-phenotype research, biomarker validation, longitudinal analysis, and multiomic cohort construction.

Challenges in United States Human Biospecimens Market

Pre-Analytical Variability and Infrastructure Requirements Complicate Standardization

Maintaining specimen integrity across collection, stabilization, transportation and storage remains technically demanding. Modern repositories must accommodate controlled room temperature, approximately −20°C, ultra-low −40°C to −80°C, and liquid-nitrogen conditions reaching −196°C. Azenta supports storage spanning ambient through −196°C and retrieval within 24 hours, illustrating the infrastructure required for scalable operations. At the same time, >80% of researchers report quality-related specimen limitations, demonstrating that large inventory volumes alone do not eliminate usability constraints.

United States Human Biospecimens Market Segmentation

The industry is segmented by specimen type, application, end use, storage type, and procurement type. Tissue specimens lead the supplied specimen dataset at approximately 44.46% in 2026, while cancer research represents approximately 34.72% of application revenue.

By Specimen Type

Tissue specimens are the largest category, valued at USD 1,441.49 million in 2026 and forecast to reach USD 2,786.95 million by 2034 at an 8.59% CAGR. The category comprises FFPE tissue, fresh-frozen tissue, tumor biopsies, and normal tissue samples, with oncology and translational research supporting utilization.

Biofluids generate USD 813.93 million in 2026 and reach USD 1,551.75 million in 2034 at an 8.40% CAGR. Cellular material rises from USD 575.18 million to USD 1,107.13 million at 8.53%, while nucleic acids increase from USD 411.58 million to USD 766.33 million at 8.08%. Within the supplied taxonomy, plasma is identified as the fastest-growing biofluid and ctDNA/cfDNA as the fastest-growing nucleic-acid subtype; subtype CAGRs were not supplied.

By Application

Cancer research is the largest application, valued at USD 1,124.68 million in 2026 and USD 2,100.27 million by 2034, registering an 8.12% CAGR. Drug discovery and development follows at USD 645.15 million in 2026 and USD 1,225.44 million by 2034 at 8.35%.

Translational and genomic research is the fastest-growing supplied application at 8.94%, followed by diagnostics and biomarker discovery at 8.74% and precision medicine at 8.64%. Diagnostics rises from USD 403.04 million in 2026 to USD 787.89 million in 2034, while translational and genomic research increases from USD 370.57 million to USD 735.14 million.

By End Use

Pharmaceutical and biotechnology companies, CROs, academic institutes, hospitals and biobanks, diagnostic laboratories, and government/non-profit organizations constitute the principal customer groups. Commercial biobanks increasingly support both research and clinical-development workflows, while large U.S. research programs operate at 600,000+ collected-sample scale and commercial repositories exceed 10 million stored specimens.

No end-use revenue or CAGR table was supplied. Consequently, numerical dominance or fastest-growing end-use rates cannot be calculated without introducing unsupported values.

By Storage Type

Storage spans −80°C cold storage, ambient stabilization, −196°C cryogenic environments, and formalin-fixed preservation. Commercial infrastructure demonstrates a broad operational range: Azenta supports controlled-room-temperature storage, +5°C to −20°C refrigeration/freezing, −40°C to −80°C ultra-low storage, and −150°C to −196°C liquid-nitrogen environments.

No storage-type revenue or CAGR values were provided. The segment's competitive differentiation therefore centers on temperature stability, backup redundancy, automated retrieval, audit trails, 24/7 inventory visibility, and sample-integrity controls rather than an unsupported quantitative ranking.

By Procurement Type

Prospective/on-demand collection enables protocol-specific sourcing, while retrospective or banked procurement provides faster access to existing inventories. Precision for Medicine reports more than 10 million repository specimens, whereas iSpecimen supports diagnostic-remnant, banked, and prospective collection pathways across its network.

No procurement-type CAGR or revenue distribution was supplied. Operationally, prospective sourcing is particularly relevant for narrowly defined cohorts, whereas banked specimens support programs prioritizing immediate availability and reduced collection lead times.

United States Human Biospecimens Market Outlook

The supplied mandatory dataset covers the United States nationally and contains no state, county, or census-region allocation. Therefore, numerical county shares cannot be derived without fabricating regional values. U.S. infrastructure nevertheless spans major biomedical hubs: Azenta lists North American repositories in Boston, Cleveland, Fresno, Indianapolis, and Plainfield, with its Boston-area facility supporting same-day local retrieval and temperatures extending to vapor-phase LN2.

National collection infrastructure is similarly distributed. All of Us reports 430+ enrollment locations, 100+ community-organization partners, 870,000+ consented participants, 597,000+ fully enrolled participants, and 612,000+ collected blood, urine, and saliva samples. These figures indicate geographically distributed sourcing across hospital, academic, government, biobank, and community-based channels, although county-specific percentage contributions are not publicly established by the supplied dataset.

Top players in United States human biospecimens market

• Discovery Life Sciences
• BioIVT
• Precision for Medicine
• Azenta Life Sciences
• iSpecimen
• Charles River Laboratories
• Thermo Fisher Scientific
• Boca Biolistics
• StemExpress
• Cureline
• Tissue Solutions
• ProteoGenex
• Indivumed
• AMSBIO
• Conversant Bio

Top Two Companies

• Discovery Life Sciences:The company maintains a strong competitive position through integrated biospecimen sourcing, specialty laboratory services, digital pathology, and biomarker-development capabilities. Its January 2025 PathAI collaboration introduced AI-enabled digital and quantitative pathology workflows into its commercial biobank operations. No authoritative public source identified in the reviewed material discloses a defensible percentage of total U.S. industry revenue for Discovery Life Sciences; assigning a numerical company share would therefore constitute an unsupported estimate. Its positioning is instead supported by its combination of commercial biobanking, tissue access, specialty testing, digital pathology and technology-enabled specimen characterization.
• BioIVT:BioIVT competes through broad biospecimen sourcing, disease-specific biological material, primary cells, blood products and research services supporting pharmaceutical and diagnostic development. In August 2024, BioIVT acquired ZenBio, expanding its capabilities in primary-cell products, exosome isolation, skin-focused research products, and blood-derived material. A verified percentage of total U.S. industry revenue attributable to BioIVT is not publicly disclosed in the reviewed sources, preventing a reliable company-share calculation. Strategically, the acquisition expands the company's addressable research workflows and strengthens its ability to supply specialized cellular material alongside traditional human biospecimens.

Recent Developments in the United States Human Biospecimens Market

• 2026: All of Us released a biospecimen table in its Controlled Tier containing information on more than 370,000 available participant samples, including blood DNA, saliva DNA, serum, and plasma.
• 2025: NIH's enhanced human-biospecimen security policy became effective October 24, introducing additional security requirements for relevant NIH-funded biospecimen activities involving U.S. persons.
• 2025: Discovery Life Sciences partnered with PathAI to deploy AI-enabled pathology technologies across its biospecimen operations, including AISight, ArtifactDetect, and TumorDetect.
• 2025: Azenta Life Sciences opened a Greater Boston biorepository supporting multiple storage temperatures, active and archival clinical-trial materials, and same-day local sample retrieval.
• 2025: iSpecimen announced that it had secured suppliers for human metapneumovirus biospecimens amid increasing research attention to hMPV, extending its infectious-disease sourcing capabilities.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, historical context for 2022–2024, and forecasts through 2034. Mandatory supplied numerical tables were treated as the primary quantitative source: specimen-type totals of USD 2,989.10 million in 2025, USD 3,242.18 million in 2026, and USD 6,212.16 million in 2034 were retained without alteration. Percentage contributions were calculated directly from supplied values. Application figures were independently retained from the supplied application table, whose total is USD 3,239.16 million for 2026 and USD 6,161.59 million for 2034; this differs from the specimen-type totals and was not artificially reconciled. Secondary research was used only for industry infrastructure, technology, regulation, participant/sample volumes, company positioning, and developments. No unsupported state, county, subsegment, end-use, storage, procurement, or company revenue-share figures were introduced.